Microbix Biosystems Inc.

Microbix Biosystems Inc.

March 06, 2015 08:00 ET

Microbix Announces Annual and Special Meeting Voting Results

TORONTO, ONTARIO--(Marketwired - March 6, 2015) - Microbix Biosystems Inc. (TSX:MBX) ("Microbix" or the "Company"), an innovator of biological products and technologies, announces the results of the Annual and Special Meeting of Shareholders which was held on March 3, 2015, at which 46.64% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the meeting. A detailed description of all resolutions that were voted on can be reviewed in the Company's Information Circular, which was filed on SEDAR on February 10, 2015. All of the nominees listed in the Information Circular were re-elected as directors of Microbix. Detailed results of the vote are set out below:

Nominee For % For Withheld % Withheld
Peter M. Blecher 32,768,754 98.07 645,923 1.93
Mark A. Cochran 32,705,954 97.88 708,723 2.12
Vaughn C. Embro-Pantalony 32,712,754 97.90 701,923 2.10
William J. Gastle 32,541,154 97.39 873,523 2.61
Andrew C. Pollock 32,705,954 97.88 708,723 2.12
Joseph D. Renner 32,802,754 98.17 611,923 1.83
Martin Marino 32,755,954 98.03 658,723 1.97
Cameron Groome 32,802,754 98.17 611,923 1.83

In addition, shareholders approved: the appointment of the Company's auditors; Collins Barrow Toronto LLP, amendments to the Company's stock option plan; and amendments to warrants held by insiders.

About Microbix Biosystems

Microbix Biosystems Inc. specializes in the development of biological solutions, including products for vaccine and diagnostics markets worldwide. The company owns intellectual property for an approved biological drug, a vaccine technology and an animal reproduction technology. Established in 1988, Microbix is headquartered in Toronto.

Microbix' pipeline of innovative technologies and products includes LumiSort® semen sexing technology for the livestock industry, Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots, and VIRUSMAX®, a proprietary technology for increasing virus yields in influenza vaccine manufacture.

Please visit www.sedar.com for recent Microbix Biosystems Inc. filings on its pipeline products and financial information.

Contact Information

  • Microbix Biosystems Inc.
    Vaughn C. Embro-Pantalony
    (905) 361-8910 (ext. 350)

    Microbix Biosystems Inc.
    Charles Wallace
    (905) 361-8910 (ext. 255)